Fractional CMO for Healthtech

I am a growth operator, not a clinician. My expertise is in building go-to-market systems that work inside regulated environments and for clinical buyers. I understand the compliance constraints, the buying committee dynamics, and the evidence standards healthtech buyers apply. I work with clinical advisors and medical affairs teams to make sure the product claims are accurate. I own the go-to-market architecture and the revenue outcome.

We agree permitted data and source access with the responsible privacy, legal and product owners before implementation. HHS guidance addresses the use and disclosure of protected health information for marketing and its authorization requirements and exceptions. I personally build approved content, campaigns and journeys within the agreed scope; audience labels alone do not establish that a use is permitted.

Diagnostic is my personal inspection of the agreed funnel, customer, campaign and measurement evidence, with a findings record and prioritized plan. Operator combines senior leadership and agreed personal implementation. We set authorized access, delivery checkpoints and observation windows for the scope. You keep the diagnostic findings whether or not we continue; see the engagement models for the choices.

Yes, this is a specific competence. The Israeli healthtech export challenge is well-defined: strong clinical evidence, limited brand presence in target markets, a sales motion that relies heavily on personal networks rather than systematic demand generation. I have helped Israeli technology companies build the credibility infrastructure - case studies, thought leadership, conference presence, analyst relations - that US and European health system buyers need before they will engage. The Diagnostic engagement is designed to show you exactly where your international go-to-market is breaking.

Fit depends on the buyer, product evidence, resources, authorized access and work needed. I can personally deliver agreed research, positioning, acquisition, conversion, lifecycle and measurement for consumer or enterprise healthtech. Qualified clinical, privacy, legal and regulatory owners retain their approval responsibilities. Advice-only support is a separate Advisory engagement.

It means using approved product evidence to answer the actual buyer’s questions and identifying what that evidence does and does not support. I personally develop and implement the selected content, campaigns and journey work with the relevant reviewers. We evaluate delivered assets and observed response separately; no fixed comparison with paid acquisition or guaranteed sales effect is implied.

The call helps define your healthtech decision, available approved evidence and the personal investigation or implementation needed. We agree authorized access, scope, reviewers and first checkpoints before reaching an evidenced diagnosis. Regulatory and clinical conclusions remain with the qualified owners.

There is no minimum term. Engagements are month-to-month, and either side can end the engagement with 30 days notice. Ending a fractional engagement involves no severance. Scope and exit terms are agreed before we start. If progress stalls, we review the scope and next steps under the agreed contract terms.